利用无创影像组学生物标志物预测癌症免疫治疗反应
研究纳入203例接受抗PD1治疗的晚期黑色素瘤和非小细胞肺癌(NSCLC)患者共1055个原发和转移病灶,基于治疗前增强CT影像开发并验证人工智能机器学习标志物以区分免疫治疗应答与否;该标志物在NSCLC病灶达AUC 0.83(P<0.001),黑色素瘤淋巴结为AUC 0.64(P=0.05),患者层面两癌种AUC均可达0.76(P<0.001),1年生存差异24%(P=0.02)。
要点
- 基于治疗前增强CT的AI影像组学标志物可区分免疫治疗应答与不应答。
- NSCLC病灶AUC达0.83(P<0.001),黑色素瘤淋巴结AUC 0.64(P=0.05)。
- 患者层面预测AUC达0.76(P<0.001),1年生存差异24%(P=0.02)。
核心结论
- 标准诊疗影像上的病灶影像学特征可能作为免疫治疗反应的无创生物标志物,并可能有助于改善新辅助和姑息治疗场景下的患者分层。
研究设计与样本
- 研究分析203例接受抗PD1治疗的晚期黑色素瘤和NSCLC患者共1055个原发和转移病灶。
- 对每个病灶的治疗前增强CT影像数据进行基于人工智能的刻画,以开发并验证能区分免疫治疗应答与不应答的无创机器学习标志物。
- 在262例NSCLC患者的独立数据集中进行基因集富集分析以明确影像学标志物的生物学基础。
主要发现
- 标志物在NSCLC病灶上达到显著性能,AUC最高0.83(P<0.001)。
- 标志物在黑色素瘤淋巴结上为临界显著,AUC 0.64(P=0.05)。
- 将病灶层面预测在患者层面合并后,两种癌症类型的免疫治疗反应预测AUC均可达0.76(P<0.001),1年生存差异为24%(P=0.02)。
- 发现与有丝分裂相关通路存在高度显著关联,提示增殖潜能增加与免疫治疗优先应答之间的关系。
临床怎么用
- 作者认为标准诊疗影像上的病灶影像学特征可能作为免疫治疗反应的无创生物标志物,并可能有助于改善新辅助和姑息治疗场景下的患者分层。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Immunotherapy is regarded as one of the major breakthroughs in cancer treatment. Despite its success, only a subset of patients responds-urging the quest for predictive biomarkers. We hypothesize that artificial intelligence (AI) algorithms can automatically quantify radiographic characteristics that are related to and may therefore act as noninvasive radiomic biomarkers for immunotherapy response. PATIENTS AND METHODS: In this study, we analyzed 1055 primary and metastatic lesions from 203 patients with advanced melanoma and non-small-cell lung cancer (NSCLC) undergoing anti-PD1 therapy. We carried out an AI-based characterization of each lesion on the pretreatment contrast-enhanced CT imaging data to develop and validate a noninvasive machine learning biomarker capable of distinguishing between immunotherapy responding and nonresponding. To define the biological basis of the radiographic biomarker, we carried out gene set enrichment analysis in an independent dataset of 262 NSCLC patients. RESULTS: The biomarker reached significant performance on NSCLC lesions (up to 0.83 AUC, P < 0.001) and borderline significant for melanoma lymph nodes (0.64 AUC, P = 0.05). Combining these lesion-wide predictions on a patient level, immunotherapy response could be predicted with an AUC of up to 0.76 for both cancer types (P < 0.001), resulting in a 1-year survival difference of 24% (P = 0.02). We found highly significant associations with pathways involved in mitosis, indicating a relationship between increased proliferative potential and preferential response to immunotherapy. CONCLUSIONS: These results indicate that radiographic characteristics of lesions on standard-of-care imaging may function as noninvasive biomarkers for response to immunotherapy, and may show utility for improved patient stratification in both neoadjuvant and palliative settings.
引用
- Trebeschi S, Drago SG, Birkbak NJ, et al. Predicting response to cancer immunotherapy using noninvasive radiomic biomarkers. Ann Oncol. 2019. PMID: 30895304. doi:10.1093/annonc/mdz108
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。